Cargando…

ERG induces taxane resistance in castration-resistant prostate cancer

Taxanes are the only chemotherapies used to treat patients with metastatic castration-resistant prostate cancer (CRPC). Despite the initial efficacy of taxanes in treating CRPC, all patients ultimately fail due to the development of drug resistance. In this study, we show that ERG overexpression in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Galletti, Giuseppe, Matov, Alexandre, Beltran, Himisha, Fontugne, Jacqueline, Miguel Mosquera, Juan, Cheung, Cynthia, MacDonald, Theresa Y., Sung, Matthew, O’Toole, Sandra, Kench, James G., Suk Chae, Sung, Kimovski, Dragi, Tagawa, Scott T., Nanus, David M., Rubin, Mark A., Horvath, Lisa G., Giannakakou, Paraskevi, Rickman, David S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Pub. Group 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4244604/ https://www.ncbi.nlm.nih.gov/pubmed/25420520 http://dx.doi.org/10.1038/ncomms6548

Ejemplares similares

Prospective Multicenter Study of Circulating Tumor Cell AR-V7 and Taxane Versus Hormonal Treatment Outcomes in Metastatic Castration-Resistant Prostate Cancer
por: Armstrong, Andrew J., et al.
Publicado: (2020)

Quantitative analysis of taxane drug target engagement of microtubules in circulating tumor cells from metastatic castration resistant prostate cancer patients treated with CRXL301, a nanoparticle of docetaxel
por: Mukhtar, Eiman, et al.
Publicado: (2020)

AR-V7 exhibits non-canonical mechanisms of nuclear import and chromatin engagement in castrate-resistant prostate cancer
por: Kim, Seaho, et al.
Publicado: (2022)

Divergent clonal evolution of castration resistant neuroendocrine prostate cancer
por: Beltran, Himisha, et al.
Publicado: (2016)

Taxane resistance in castration-resistant prostate cancer: mechanisms and therapeutic strategies
por: Bumbaca, Brandon, et al.
Publicado: (2018)

Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
por: Jiménez, Natalia, et al.
Publicado: (2020)

Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Androgen receptor variant shows heterogeneous expression in prostate cancer according to differentiation stage
por: Gjyrezi, Ada, et al.
Publicado: (2021)

Circulating Cell-Free DNA as Biomarker of Taxane Resistance in Metastatic Castration-Resistant Prostate Cancer
por: Francini, Edoardo, et al.
Publicado: (2021)

Isolation and characterization of circulating tumor cells in prostate cancer
por: Diamond, Elan, et al.
Publicado: (2012)

Predictive value of stathmin-1 and osteopontin expression for taxan resistance in metastatic castrate-resistant prostate cancer
por: Aksoy, Asude, et al.
Publicado: (2017)

Targeting Taxanes to Castration-Resistant Prostate Cancer Cells by Nanobubbles and Extracorporeal Shock Waves
por: Marano, Francesca, et al.
Publicado: (2016)

Inhibition of Mps1 kinase enhances taxanes efficacy in castration resistant prostate cancer
por: Sarwar, Sadia, et al.
Publicado: (2022)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

Mechanisms of Taxane Resistance
por: Maloney, Sara M., et al.
Publicado: (2020)

Cabazitaxel: A novel taxane for metastatic castration-resistant prostate cancer-current implications and future prospects
por: Abidi, Afroz
Publicado: (2013)

Autotuning of Exascale Applications With Anomalies Detection
por: Kimovski, Dragi, et al.
Publicado: (2021)

Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2013)

Effects of Black Raspberries and Their Ellagic Acid and Anthocyanin Constituents on Taxane Chemotherapy of Castration-Resistant Prostate Cancer Cells
por: Eskra, Jillian N., et al.
Publicado: (2019)

Glutamine and Cholesterol Plasma Levels and Clinical Outcomes of Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Taxanes
por: Marín-Aguilera, Mercedes, et al.
Publicado: (2021)

Darolutamide Maintenance in Patients With Metastatic Castration-Resistant Prostate Cancer With Nonprogressive Disease After Taxane Treatment (SAKK 08/16)
por: Gillessen, Silke, et al.
Publicado: (2023)

Correction: Interaction between c-jun and Androgen Receptor Determines the Outcome of Taxane Therapy in Castration Resistant Prostate Cancer
por: Tinzl, Martina, et al.
Publicado: (2018)

Differential responses to taxanes and PARP inhibitors in ATM‐ versus BRCA2‐mutated metastatic castrate‐resistant prostate cancer
por: Su, Christopher T., et al.
Publicado: (2022)

Bone Marrow Recovery and Subsequent Chemotherapy Following Radiolabeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 in Men with Metastatic Castration-Resistant Prostate Cancer
por: Tagawa, Scott T., et al.
Publicado: (2013)

TMPRSS2- Driven ERG Expression In Vivo Increases Self-Renewal and Maintains Expression in a Castration Resistant Subpopulation
por: Casey, Orla M., et al.
Publicado: (2012)

Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer
por: Song, Wan, et al.
Publicado: (2016)

Clonal Evaluation of Prostate Cancer Foci in Biopsies with Discontinuous Tumor Involvement by Dual ERG/SPINK1 Immunohistochemistry
por: Fontugne, Jacqueline, et al.
Publicado: (2016)

Regulation of ERG3, ERG6, and ERG11 Genes in Antifungal-Resistant isolates of Candida parapsilosis
por: Lotfali, Ensieh, et al.
Publicado: (2017)

Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
por: Armstrong, Andrew J., et al.
Publicado: (2019)

Targeting LIM kinases in taxane resistant tumors
por: Prunier, Chloé, et al.
Publicado: (2016)

Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy
por: Shimizu, Yasuomi, et al.
Publicado: (2018)

An ERG Gene Analysis in Two Cases with Metastatic Castration-resistant Prostate Cancer in Which Abiraterone Demonstrated Long-term Efficacy
por: Yoshizawa, Tsuyoshi, et al.
Publicado: (2019)

Prediction of Acquired Taxane Resistance Using a Personalized Pathway-Based Machine Learning Method
por: Kim, Young Rae, et al.
Publicado: (2019)

Taxane-based Chemotherapy Induced Androgen Receptor Splice Variant 7 in Patients with Castration-Resistant Prostate Cancer: A Tissue-based Analysis
por: Shim, Myungsun, et al.
Publicado: (2019)

Mutations in BRCA2 and taxane resistance in prostate cancer
por: Nientiedt, Cathleen, et al.
Publicado: (2017)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Long Noncoding RNAs in Taxane Resistance of Breast Cancer
por: Chen, Hailong, et al.
Publicado: (2023)

Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
por: Mehra, Niven, et al.
Publicado: (2018)

CETSA-based target engagement of taxanes as biomarkers for efficacy and resistance
por: Langebäck, Anette, et al.
Publicado: (2019)

Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells
por: Wang, Harris, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_ok57pti7jv99rn7br7qfbqr0uc